4/A: ProPhase Labs Director Ted Karkus Amends SEC Filing to Correct Option Grant Details

Ted Karkus, CEO & Chairman of ProPhase Labs, files an amended Form 4 to correct the reporting of a 400,000 share option grant.

Summary

• Ted Karkus, CEO & Chairman of ProPhase Labs, filed an amended Form 4 with the SEC.
• The amendment corrects a previous filing from March 19, 2024, regarding an option grant.
• The correction pertains to Table II, Box 5, where the share amount was inadvertently reported under the wrong subheading.
• The corrected filing clarifies that Karkus was granted options to purchase 400,000 shares of ProPhase Labs common stock at an exercise price of $6.
• The options vest in four equal installments, with 25% vesting immediately and the remainder vesting annually over the next three years.
• The options expire on March 17, 2031.

Sentiment

Score: 6

Explanation: The document is a neutral regulatory filing correcting a previous error. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

This filing is a routine disclosure related to executive compensation and is standard practice for publicly traded companies.

Stakeholder Impact

• The correction ensures transparency for shareholders regarding executive compensation.

Key Dates

Keywords

Form 4, ProPhase Labs, Option Grant, Ted Karkus, Amendment, SEC Filing, Beneficial Ownership